Sector
PharmaceuticalsOpen
₹212.01Prev. Close
₹214.44Turnover(Lac.)
₹160.13Day's High
₹216.64Day's Low
₹210.0952 Week's High
₹328.0452 Week's Low
₹130.48Book Value
₹36.53Face Value
₹2Mkt Cap (₹ Cr.)
1,423.2P/E
35.86EPS
5.98Divi. Yield
1.167 Aug 2024
12:00 AM
AGM
Announcement Date: 07 Aug, 2024
29 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
20 May 2024
12:00 AM
Dividend
Dividend Amount: 5
Record Date: 06 Sep, 2024
23 Oct 2024
12:00 AM
Split
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 13.22 | 13.1 | 13.1 | 13.1 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 174.18 | 145.79 | 119.66 | 108.83 |
Net Worth | 187.4 | 158.89 | 132.76 | 121.93 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 187.94 | 158.56 | 126.53 | 143.87 |
yoy growth (%) | 18.52 | 25.31 | -12.05 | 0.26 |
Raw materials | -80.77 | -56.18 | -61.11 | -58.94 |
As % of sales | 42.97 | 35.43 | 48.29 | 40.97 |
Employee costs | -53.98 | -50.37 | -41.87 | -40.95 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 21.87 | 9.41 | -11.62 | 1.59 |
Depreciation | -1.08 | -1.12 | -0.31 | -1.99 |
Tax paid | -4.81 | -1.54 | 0.07 | -2.53 |
Working capital | 16.88 | -7.6 | -14.27 | 6.47 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 18.52 | 25.31 | -12.05 | 0.26 |
Op profit growth | 123.59 | -176.82 | -292.53 | -51.15 |
EBIT growth | 125.46 | -190.51 | -358.5 | -54.72 |
Net profit growth | 116.72 | -168.14 | -197.35 | 264.59 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Manish Gupta
Chairman & Non Executive Dir.
Harsha Raghavan
Independent Director
Debasis Bikash Nandy
Independent Director
Radhika Dudhat
Independent Director
Pallavi Dinodia
Non Executive Director
Prithipal Singh Kochhar
T-210 J,
Shahpur Jat,
New Delhi - 110049
Tel: 91-011-46181100/46109900
Website: http://www.jagsonpal.com
Email: skmata@jagsonpal.com; cs@jagsonpal.com
F-65 1st Floor,
Okhla Industrial Are, Phase-I,
New Delhi-110020
Tel: 91-11-41406149-52
Website: www.mcsdel.com
Email: mcsdel@vsnl.com
Summary
Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The...
Read More
Reports by Jagsonpal Pharmaceuticals Ltd
What is the Jagsonpal Pharmaceuticals Ltd share price today?
What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?
What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd?
What is the 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd?
What is the CAGR of Jagsonpal Pharmaceuticals Ltd?
What is the shareholding pattern of Jagsonpal Pharmaceuticals Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.